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Objective. Systemic sclerosis (SSc) is a complex autoimmune disease in which interferons (IFNs) may play an essential role. We
hypothesized that type I and III IFNs may be found in increased levels in patients and be responsible for SSc autoimmune status.
Methods. Type I and III IFN and ISG basal expression proﬁles were measured by qPCR using RNA from PBMCs of patients and
controls.Results.TypeIIFNsareincreasedinSScpatients,whilenoinductionoftypeIIIIFNswasdetected.Thisinductioncannot
be related to IRF7, since no upregulation of this gene was seen on patients. Of the ISGs tested, 2 5 OAS levels were increased in
patients, while 6–16 and MxA levels were not. Conclusions. While there is no indication of type III IFN induction, increased levels
of type I IFNs may lead to abnormal regulation of ISGs that can be responsible for immune system alterations described for SSc.
1.Introduction
Systemic sclerosis (SSc) is a complex autoimmune disease
of unknown aetiology characterized by excessive ﬁbrosis of
the skin and internal organs, presence of autoantibodies to
nuclear antigens, and vascular damage [1–4]. Several genetic
and environmental agents have been proposed to be respon-
sible for causing SSc. Among these agents are infections,
toxin exposure, single nucleotide polymorphisms (SNPs),
and interferon treatment [5–7]. Regardless of the origin, the
immune system on SSc patients shows evidence of homeo-
static alterations, including increased levels of chemokines
in blood serum and diﬀerent populations of lymphocytes in
peripheral blood mononuclear cells (PBMCs). In addition
to these alterations, there is increased evidence that the
interferon (IFN) system is modiﬁed in patients with SSc [8–
15].
IFNs are immunomodulatory cytokines that act as an
important link between the innate and adaptive immune
systeminvertebrates.IFNsbindtodistinctcellularreceptors,
and their biological activities are mediated by the regulation
of interferon stimulated genes (ISGs). IFNs can be divided
into three types based on receptor binding and homology.
Type I and type III IFNs are important regulators of innate
immunity and are produced after stimulation of pattern
recognition receptors in order to initiate and regulate the
immune response. One of the main pathways leading to
type I and III IFNs induction depends on the induction and
activation of IRF7. Almost every cell type is able to produce
these IFNs after stimulation, but its main producers are cells
fromtheimmunesystemsuchasplasmacytoiddentriticcells.
Type I and III IFNs have redundant biological activities,
even though they bind to diﬀerent cellular receptors and
have distinct structures. IFN gamma, the only known type2 International Journal of Rheumatology
II IFN, has distinct biological activities and is important for
the regulation of adaptative immunity [16, 17]. The innate
immune system and type I IFNs have been proposed as
important factors in the initiation and maintenance of some
autoimmune diseases, and the inﬂuence of type I IFNs in SSc
has not been studied in detail [18–20]. Several activities of
type I and type III IFNs are redundant, and until now there
has been no description of type III IFNs participation in SSc
or other autoimmune diseases. An SNP in one chain of the
type III IFN receptor (IL10R2) has been associated with SSc,
indicating that at least responsivity to these molecules may
be important for the disease [21].
Previous studies have shown an increase of several ISGs
in PBMCs of patients with autoimmune diseases such as
systemic lupus erythematosus (SLE) and type I diabetes
[10, 22]. Diﬀerential induction of ISGs in blood cells and
ﬁbroblasts from patients has already been described [19,
23–25]. When PBMC gene expression was compared by
microarray between healthy donors and SSc patients, several
I S G sw e r ec h a r a c t e r i z e da sd i ﬀerentially induced. Some of
these genes were also found in patients with SLE, which
is an autoimmune disease marked by several alterations in
the type I IFN system [4, 24]. Levels of 2 5  oligoadenylate
synthetase (2 5 OAS) and double-stranded RNA-activated
protein kinase (PKR), two ISGs, are found at higher levels
in ﬁbroblasts from SSc patients when compared to controls
[19]. To date, there is no direct evidence of abnormal
induction of type I IFNs in SSc, even thought cells treated
with sera from SSc patients produce more IFN alpha and
other cytokines than cells treated with sera from controls
[12]. These ﬁndings suggest that IFNs may also be important
in SSc pathology.
In this paper, we show that PBMCs from SSc patients
basally expressed more type I IFNs (alpha and beta) than
PBMCs from healthy donors. In addition, there was no
detectable basal induction of type III IFNs in patients or
healthy donors. When ISGs were measured, we observed
increased 2 5 OAS basal levels, consistent with previous
studies. These ﬁndings suggest that, similar to other autoim-
mune diseases, type I IFNs play an important role in SSc.
2. Methods
2.1. Blood Donors. Ten patients fulﬁlling the American
College of Rheumatology preliminary criteria for diagnosis
of diﬀuse SSc and four healthy subjects were chosen as blood
donors (Table 1). Before donating blood, each subject read
and signed an informed consent previously approved by
the Ethics Committee of the Universidade Federal de Minas
Gerais, Brazil.
2.2. Cells and PBMC Fractionation. Vero cells (African green
monkey kidney cell line) were obtained from the ATCC
and grown at 37◦C in Dulbecco’s modiﬁed Eagle’s medium
(DMEM) supplemented with 2mM glutamine, 5% fetal
calf serum (Cultilab, Campinas, SP, Brazil), and antibiotics.
PBMCs from healthy donors or SSc patients were puri-
ﬁed using the Ficoll-Hypaque puriﬁcation technique [26].
Table 1: Information about the subjects that consented to take part
in this research.
Sex Age
(years)
Disease time
(years)1 Treatment ANA titer
P1 F 31 1 Prednisone >1/320
P2 F5 4 5 Methotrexate
Prednisone <1/10240
P3 M3 5 5 Methotrexate
Prednisone >1/5120
P4 M 29 1 Prednisone >1/640
P5 M4 0 7 — <1/10240
P6 F3 0 2 — >1/320
P7 F5 0 5 — >1/80
P8 M5 6 6 — <1/10240
P9 F5 8 1 1 Methotrexate
Prednisone >1/80
P10 F7 0 2 0 — >1/640
C1 M3 9 — — N o t t e s t e d
C2 F3 2 — — N o t t e s t e d
C3 M2 5 — — N o t t e s t e d
C4 F2 4 — — N o t t e s t e d
C: control; P: patient; M: male; F: female; —: not treated.
1Dated from the onset of the ﬁrst non-Raynaud’s symptom.
Brieﬂy, fresh blood collected in vacuum tubes containing
heparin was diluted in an equal volume of 1X phosphate
buﬀered saline (PBS). Twenty milliliters of the diluted blood
were carefully added over 10mL of Ficoll and centrifuged
at 400×g for 30min. The layer containing PBMCs was
collected and washed once in 1X PBS, and the cells were
counted. One million cells were pelleted and used for RNA
extraction.
2.3. RNA Extraction, DNase Treatment, Reverse Transcription
and Quantitative PCR (qPCR). Total cellular RNA was
extracted using the RNeasy mini kit (QIAGEN). After the
extraction, one microgram of RNA was treated with 1U of
DNase I enzyme (BIOLABS), and after treatment the RNA
was used as template in reverse transcriptions carried out
usingMMLVreversetranscriptase(PROMEGA).Thesesteps
were performed as described by the manufacturers. Real
time PCRs were performed in a Step-One Real-Time PCR
machine (Applied Biosystem) using the relative quantiﬁca-
tion methodology. The results were analyzed using StepOne
Softwarev2.2,andalldatawereexpressedasaratiorelativeto
the beta-actin level. PCR primers used for human genes are
listedbelow:IFNalpha2forward5 -TTGACCTTTGCTTTA-
CTGGT-3 and reverse 5 -CACAAGGGCTGTATTTCTTC-
3 .I F Nb e t af o r w a r d5  -CCTGTGGCAATTGAATGGGAG-
GC-3  and reverse 5 -CAGGTAGATGGTATAGCGTGG-3 .
IFN lambda1 forward 5 -CTTCCAAGCCCACCCCAACT-
3  and reverse 5 -GGCCTCCAGGACCTTCAGC-3 .I F N
lambda2/3 forward 5 -TTTAAGAGGGCCAAAGATGC-3 
and reverse 5 -TGGGCTGAGGCTGGATACAG-3 .I R F - 7
forward 5 -CAAGTGCAAGGTGTACTGG-3  and reverse
5 -CAGGTAGATGGTATAGCGTGG-3. 2 5 OAS forwardInternational Journal of Rheumatology 3
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Figure 1: Type I and type III IFN mRNA basal levels in PBMCs from healthy donors and SSc patients. PBMCs from healthy donors and SSc
patients were puriﬁed, and total RNA extraction was performed. The RNA obtained was used as template in reverse transcription reactions,
and the resulting cDNA was used in real-time PCRs to measure IFN alpha (a), IFN beta (b), IFN lambda1 (c), and IFN lambda 2/3 (d).
5 -AACTGCTTCCGACAATCAAC-3  and reverse 5 -CCT-
CCTTCTCCCTCCAAAA-3 .M x Af o r w a r d5  -ATCCTG-
GGATTTTGGGGCTT-3  and reverse 5 -CCGCTTGTC-
GCTGGTGTCG-3 .6 – 1 6f o r w a r d5  -CATGCGGCAGAA-
GGCGGTAT-3  and reverse 5 -CGACGGCCATGAAGG-
TCAGG-3 .B e t a - a c t i nf o rw a r d5  -CCAACCGCGAGAAGA-
TGA-3  and reverse 5 -CCAGAGGCGTACAGGGATAG-3 .
2.4. IFN Titration. After cell fractionation by the Ficoll-
Hypaque technique, one milliliter of sera was collected from
each donor and frozen at −70◦C until use. At the time of
titration, each serum sample was serially diluted from 1:2 to
1:4096andusedtotreat96-wellplatesofVerocellswith90%
conﬂuency. Eighteen hours after treatment, the medium was
discarded and the cells were infected with 104 TCID50/mL
of Encephalomyocarditis virus (EMCV). The infection was
monitored for 48 hours, at which time the plates were
ﬁxed with 3.7% formaldehyde before being stained with 1%
crystal violet (adapted from [27]). Alongside the samples,
the following controls were used: 600U/mL of recombinant
human IFN alpha 2a (Roche) and a negative serum sample
to which 600U/mL of recombinant human IFN alpha 2a
(Roche) was added.
2.5. Statistical Analysis. Student’s t-test and nonparametric
Mann-Whitney test were used to analyze the results. Dif-
ferences of P<0.05 were considered to be statistically
signiﬁcant.AnalysesweremadeusingtheGraphPadSoftware
(USA)
3. Results
The expression proﬁle of type I and type III IFNs was
measuredbyqPCRusingRNAfromPBMCsfreshlycollected
from SSc patients or controls. We observed that the basal
levels of IFN alpha2 and IFN beta were increased in patients
while there was little or no expression of these genes on
healthy donors (Figures 1(a) and 1(b)). When type III
IFNs were measured, we observed that the basal level of
IFN lambda1 and lambda2/3 was the same in both groups
(Figures 1(c) and 1(d)). These results were obtained from
cells without any treatment or culture, indicating that these
genes might be normally induced in patients. We also4 International Journal of Rheumatology
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Figure 2: Basal levels of IRF-7 and ISGs in PBMCs from healthy donors and SSc patients. PBMCs from healthy donors and SSc patients
were puriﬁed, and total RNA extraction was performed. The RNA obtained was used as template in reverse transcription reactions, and the
resulting cDNA was used in real-time PCRs to measure IRF-7 (a), 2 5 OAS (b), 6–16 (c), and MxA (d) levels.
attempted to detect IFN proteins in sera from patients and
controls through a biological assay commonly used for IFN
titration. However we were unable to detect any activity
higher than the detection limit of the assay (20IU/mL).
Our controls worked perfectly, indicating that the negative
resultsobtainedwerenotduetoseratoxicityorexperimental
artifacts (data not shown).
In addition to IFN basal levels, we also measured IRF7,
2 5 OAS,MxA,and6–16basallevelsinPBMCsfrompatients
and controls. IRF7 is an important factor for type I and type
III IFN induction, whereas the other genes are ISGs that
are commonly induced by type I and type III IFNs. There
was no statistically signiﬁcant diﬀerence in the levels of IRF7
(Figure 2(a)) between patients and controls. Similarly, there
wasnodiﬀerencebetweenlevelsofMxA(Figure 2(c))and6–
16 (Figure 2(d)). However a diﬀerence on 2 5 O A Sl ev e l sw a s
detected, and this gene basal expression level was increased
in patients but not in controls (Figure 2(b)).
4. Conclusions
IFNs are cytokines with antiviral, antiproliferative, and
immunomodulatory activities. Type I IFNs have been impli-
cated in the pathogenesis of several known autoimmune
diseases. However, the inﬂuence of type III IFNs in these
diseases is not yet known, despite the similarities in the
biologicalactivitiesoftheseIFNtypes.SScisanautoimmune
disease with unknown etiology in which the immune system
homeostasis is severely compromised. To date there has been
little information about the inﬂuence of IFNs in SSc patients
in the literature and no direct evidence of type I or type III
IFN basal induction in patients.
In this paper, we show that some components of
the IFN system can be found at higher levels in freshly
puriﬁed PBMCsfromSScpatients,comparedwithcellsfrom
controls. Increased basal expression of IFN alpha2 and IFN
beta (type I IFNs) was detected in SSc patients, while there
was no diﬀerence between the basal levels of IFN lambda1
and IFN lambda2/3 (type III IFNs) in patients and controls
(Figure 1). These results show that, at least for mRNA levels,
there is a higher expression of type I IFNs by PBMCs from
SSc patients than from controls. This abnormal expression,
especially in the case of IFN alpha2, is consistent with the
status of autoimmunity in several other diseases and can
have a major role in initiating and maintaining the disease.
High levels of IFN beta can be even more dramatic for an
autoimmune status, since this IFN has similar biological
activities to IFNs alpha but is even more potent [28]. WeInternational Journal of Rheumatology 5
also tried to titrate IFN protein levels on sera obtained from
patients and controls, but the levels were below our limit of
detection(20IU/mL).Consideringthatthistitrationmethod
is able to detect any mixture of IFNs capable of inducing
antiviral activity in host cells, we can hypothesize that even
though IFN levels are increased on SSc, they are not found in
high levels. Methodologies with greater sensitivity must be
used in order to detect and measure type I IFN proteins in
SSc patients sera.
Expression levels of IRF7, an inducible transcription
factor responsible for type I and type III IFN gene induc-
tion [29], were not altered between patients and controls
(Figure 2(a)). This ﬁnding leads us to conclude that IFN
alpha2 and beta are being induced by another stimulus
in the disease, which is speciﬁc to their induction and is
not common to type III IFNs induction. 2 5 OAS basal
expression levels were higher in patients than in controls
(Figure 2(b)). This gene is also found at higher levels in SLE
patients [30]. Diﬀerential induction of 2 5 OAS is consistent
with a previous study that used ﬁbroblasts from SSc patients,
in which higher basal levels of 2 5 OAS were detected when
compared to control ﬁbroblasts [19]. It also indicates that
there is, at least to some degree, some similarity between
alterations in the skin and blood cells of SSc patients.
Other measured ISGs, 6–16, and MxA were not diﬀerentially
expressed between patients and controls (Figures 2(c) and
2(d)). The factors leading to this diﬀerential induction on
ISGs are unknown, but could be due to cell exposure to var-
ious IFN subtypes abnormally expressed during the disease.
The capacity of SSc sera to induce cytokines in treated cells
[31] supports this observation, since this activation probably
occurs due to cytokines and other molecules in the plasma.
Based on these ﬁndings, we hypothesize that the IFN
system is modiﬁed in SSc. By still unknown mechanisms, at
least IFNs alpha2 and IFN beta are induced in patients by
a pathway that does not induce type III IFNs. Type I IFNs
produced by patients’ cells circulate and through activation
of certain subsets of ISGs maintain the autoimmune status of
SSc.Thesemoleculesareimportant links betweeninnate and
adaptative immune responses and can, among other actions,
activate immune cells to improve autoantigens detection
and autoantibodies production [32]. It has been already
described that IFN alpha2 can induce TLR3 activation in
SSc ﬁbroblasts in culture [33]. This activation can also be
happening in vivo by type I IFNs naturally produced by
PBMCs, corroborating our hypothesis. IFN beta activation is
a novel ﬁnding on the disease and can be of great importance
to SSc altered immune homeostasis. Even though there is
some redundancy between the activity of type I and type III
IFNs, we could not link type III IFNs to SSc, at least when
PBMCs are involved. Future experiments with higher sample
size and using distinct cell populations isolated from total
PBMCs are essential to further investigate these results.
These ﬁndings are of great importance to our under-
standing of the pathogenesis and pathology of SSc. Increased
basal levels of type I IFNs can lead to abnormal activation
of ISGs and undesirable side eﬀects on the patients, even
without interference by type III IFNs. The diﬀerential
expression proﬁle of ISGs detected in PBMCs is consistent
with the proﬁle found previously in ﬁbroblasts [19]a n d
could be a signature related to the disease. These unique
modiﬁcations in the IFN response may be considered as
candidates for SSc biomarkers and can be considered for
further studies as diagnostic tools for SSc.
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